Actinium Pharmaceuticals (ATNM) Non-Current Assets (2012 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Non-Current Assets of $2.2 million for Q1 2026, down 0.64% year-over-year from $2.2 million in Q1 2025, and down 9.06% quarter-over-quarter from $2.4 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Non-Current Assets (2012 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Non-Current Assets for 15 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 0.64% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $8.3 million (down 16.32% YoY), while the FY2025 annual figure was $2.4 million, changed 0.04% from the prior year.
- Non-Current Assets retreated to $2.2 million in Q1 2026 per ATNM's latest filing, from $2.4 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.5 million in Q2 2023 and bottomed at $509000.0 in Q1 2022.
- Historically, Non-Current Assets has averaged $2.7 million across 5 years, with a median of $2.8 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets slumped 62.3% — and 2023, when it jumped 583.69%.
- Actinium Pharmaceuticals' Non-Current Assets stood at $3.2 million in 2022, then dropped by 2.09% to $3.2 million in 2023, then slipped by 24.8% to $2.4 million in 2024, then advanced by 0.04% to $2.4 million in 2025, then fell by 9.06% to $2.2 million in 2026.
- Business Quant data shows ATNM's Non-Current Assets at $2.2 million in Q1 2026, $2.4 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Actinium Pharmaceuticals | 34.85 Mn | 34.85 Mn | - | 2.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.42 Mn |
| Mar 31, 2026 | 2.18 Mn |
| Dec 31, 2025 | 2.39 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 2.39 Mn |
| Sep 30, 2024 | 2.59 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Mar 31, 2024 | 2.98 Mn |
| Dec 31, 2023 | 3.18 Mn |
| Sep 30, 2023 | 3.35 Mn |
| Jun 30, 2023 | 3.51 Mn |
| Mar 31, 2023 | 3.48 Mn |
| Dec 31, 2022 | 3.25 Mn |
| Sep 30, 2022 | 3.39 Mn |
| Jun 30, 2022 | 3.50 Mn |
| Mar 31, 2022 | 509,000.00 |
| Dec 31, 2021 | 639,000.00 |
| Sep 30, 2021 | 1.22 Mn |